Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 2,237 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 2,237 shares of Relay Therapeutics stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $18.61, for a total value of $41,630.57. Following the completion of the transaction, the insider owned 407,660 shares in the company, valued at approximately $7,586,552.60. The trade was a 0.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Relay Therapeutics Stock Performance

Relay Therapeutics stock opened at $19.45 on Friday. Relay Therapeutics, Inc. has a 52 week low of $3.03 and a 52 week high of $20.79. The stock has a market capitalization of $3.73 billion, a P/E ratio of -12.39 and a beta of 1.67. The stock has a fifty day moving average of $17.06 and a 200-day moving average of $13.03.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.58 million. On average, research analysts forecast that Relay Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

RLAY has been the subject of several research analyst reports. Zacks Research downgraded shares of Relay Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Wall Street Zen raised Relay Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. JonesTrading upgraded Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. UBS Group set a $26.00 price objective on Relay Therapeutics in a research report on Tuesday, May 19th. Finally, JPMorgan Chase & Co. started coverage on Relay Therapeutics in a report on Wednesday, July 8th. They issued an “overweight” rating and a $28.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Relay Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $24.92.

Key Relay Therapeutics News

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Analysts at Zacks said Relay Therapeutics may beat consensus earnings expectations in its upcoming report, potentially providing a near-term catalyst for RLAY. The preview cites favorable expectations but does not represent an actual earnings result. Relay Therapeutics Expected to Beat Earnings Estimates
• Positive Sentiment: Relay’s breast cancer program has helped revitalize investor interest in the clinical-stage biotechnology company, although the opportunity faces intense competition from other drug developers. Relay Therapeutics Revitalized by Breast Cancer Program
• Neutral Sentiment: Relay Therapeutics will release second-quarter 2026 financial results and corporate highlights after the market closes on August 6. Investors will likely focus on pipeline progress, cash resources and guidance for upcoming clinical development. Relay Therapeutics to Announce Second-Quarter Results
• Neutral Sentiment: Three insiders, including CFO Thomas Catinazzo, sold a combined 4,444 shares at an average price of $18.61. The filings state the sales were made to cover tax withholding obligations tied to vested equity awards, and each insider retained a substantial ownership position, reducing the bearish significance.
• Negative Sentiment: The company remains a clinical-stage biotechnology firm, so its valuation depends heavily on successful development and commercialization of its pipeline. Competitive pressure in breast cancer could limit the potential upside and increase execution risk.

Hedge Funds Weigh In On Relay Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in RLAY. Commodore Capital LP acquired a new position in shares of Relay Therapeutics during the second quarter worth $46,191,000. Casdin Capital LLC grew its stake in shares of Relay Therapeutics by 14.7% in the fourth quarter. Casdin Capital LLC now owns 13,003,574 shares of the company’s stock worth $110,010,000 after purchasing an additional 1,662,193 shares during the last quarter. Perceptive Advisors LLC increased its holdings in Relay Therapeutics by 412.3% in the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock valued at $97,024,000 after purchasing an additional 7,847,896 shares during the period. Vanguard Group Inc. increased its holdings in Relay Therapeutics by 3.1% in the fourth quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock valued at $81,990,000 after purchasing an additional 295,701 shares during the period. Finally, Bellevue Group AG raised its position in Relay Therapeutics by 1.4% during the 3rd quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock worth $43,564,000 after purchasing an additional 114,740 shares during the last quarter. 96.98% of the stock is currently owned by institutional investors and hedge funds.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.